PD Dr. Michael Erdmann



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care (2024) Heinlein L, Maron RC, Hekler A, Haggenmüller S, Wies C, Utikal JS, Meier F, et al. Journal article Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study (2024) Beckmann M, Schlüter J, Erdmann M, Kramer R, Cunningham S, Hackstein H, Zimmermann R, Heinzerling L Journal article Metastasiertes ekkrines Porokarzinom bei einem jungen Patienten (2024) Kramer R, Agaimy A, Berking C, Erdmann M Journal article Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma (2024) Patalakh I, Wandersee A, Schlüter J, Erdmann M, Hackstein H, Cunningham S Journal article, Original article Gleichzeitiges Auftreten zweier malignomverdächtiger Hautveränderungen (2024) Kaufmann M, Erdmann M, Schliep S, Voskens C, Berking C, Bauerschmitz J Journal article Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma (2024) Brinker TJ, Chanda T, Hauser K, Hobelsberger S, Bucher TC, Garcia CN, Wies C, et al. Journal article Spatial cell graph analysis reveals skin tissue organization characteristic for cutaneous T cell lymphoma (2024) Sarkar S, Möller A, Hartebrodt A, Erdmann M, Ostalecki C, Baur A, Blumenthal DB Journal article, Original article Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary (2024) Persa OD, Cecile Hassel J, Steeb T, Erdmann M, Karimi B, Stege H, Klespe KC, et al. Journal article Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events (2024) Koch E, Petzold A, Dippel E, Erdmann M, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024) Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al. Journal article